Broth Microdilution

Broth microdilution is a quantitative method for antimicrobial susceptibility testing (AST), standardized by bodies like CLSI and under ISO 20776-1. It involves serially diluting an antimicrobial in broth within a microtiter plate, inoculating it with bacteria, and identifying the Minimum Inhibitory Concentration (MIC)—the lowest concentration preventing visible growth. Within the ISO 31000 risk management framework, this technique is vital for the 'Risk Analysis' step. It provides precise quantitative data (MIC values) to assess the risk of treatment failure or R&D setbacks due to drug resistance, unlike qualitative methods like disk diffusion. This data enables granular risk evaluation and informs strategic decisions in healthcare and pharmaceutical development.

In ERM, its application follows the ISO 31000 process. 1. **Risk Identification**: A hospital or pharma company identifies Antimicrobial Resistance (AMR) as a key operational and strategic risk. 2. **Risk Analysis**: Broth microdilution is performed per ISO 20776-1 to generate Key Risk Indicators (KRIs) like MIC50 and MIC90 values against target pathogens. For instance, a drug developer might set a risk threshold where an MIC90 > 2 mg/L against a key pathogen elevates the project's risk profile. 3. **Risk Treatment**: Based on this data, risk treatment plans are formulated. A hospital might update its antibiotic stewardship program, while a pharma company could decide to terminate a drug candidate. This data-driven approach leads to measurable outcomes, such as a reduction in hospital-acquired infections or minimizing sunk costs in non-viable drug development projects.

1. **High Costs**: Implementing and maintaining standardized testing compliant with ISO 20776-1 requires significant investment in equipment, reagents, and skilled personnel, challenging for smaller biotech firms. 2. **Data Integration**: Integrating MIC lab data with clinical outcomes and epidemiological data to build predictive risk models is complex and requires specialized data science expertise often lacking in-house. 3. **Regulatory Lag**: Keeping pace with evolving data requirements from international regulatory bodies like the FDA and EMA for new drug approvals is a major challenge. Mitigation strategies include adopting automated systems to reduce labor costs, collaborating with academic institutions for advanced data modeling, and establishing a dedicated regulatory intelligence team to monitor global standards.

Winners Consulting specializes in broth microdilution for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact